Literature DB >> 10985509

Simian virus (SV) 40 like sequences in cell lines and tumour biopsies from Australian malignant mesotheliomas.

B R McLaren1, T Haenel, S Stevenson, S Mukherjee, B W Robinson, R A Lake.   

Abstract

BACKGROUND: Simian virus (SV) 40 sequences have been found in some, but not all studies of mesotheliomas. This virus is known to cause tumours in rodents but its role in human oncogenesis remains controversial. AIMS: The aim of this study therefore was to determine whether SV40 is associated with the development of mesotheliomas in Australia. The absence of the virus or its gene products in tissue derived from mesotheliomas would detract from this possibility.
METHODS: We used polymerase chain reaction from three pairs of primers to amplify different regions of the large T antigen from DNA from cell lines and cDNA from both cell lines and an independent set of tumour biopsies from patients with mesothelioma.
RESULTS: We examined five human mesothelioma cell lines that were established in our laboratories. In addition, we examined several tumour biopsies from seven different patients. SV40 like sequences were present in all the cell lines and in at least one sample from each of the patients examined.
CONCLUSIONS: The large T antigen of SV40 or an SV40 like virus is expressed in Australian mesotheliomas and therefore could be aetiologically-associated with tumourigenesis. Alternatively, these sequences could be expressed subsequent to the development of the disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10985509     DOI: 10.1111/j.1445-5994.2000.tb02050.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  2 in total

1.  p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.

Authors:  J Creaney; B M McLaren; S Stevenson; A W Musk; N de Klerk; B W Robinson; R A Lake
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

Review 2.  Association Between Simian Virus 40 and Human Tumors.

Authors:  John Charles Rotondo; Elisa Mazzoni; Ilaria Bononi; Mauro Tognon; Fernanda Martini
Journal:  Front Oncol       Date:  2019-07-25       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.